Bovie Medical Announce Sales Channel Partnership with CONMED for PlazXact™
20 January 2017 - 12:00AM
Business Wire
Bovie Medical (NYSE MKT: BVX), announced that it
has entered into a global sales channel partnership agreement with
CONMED (NASDAQ: CNMD) for its PlazXact™ Ablator, which will
be marketed as the UltrAblator Bipolar® series effective in March
2017.
Bovie Medical’s CEO, Robert L. Gershon noted, “Partnering with a
company of CONMED’s reputation builds on Bovie’s strategy to scale
our innovative products through strategic sales channel
partnerships that provide immediate access to large addressable
markets. We are proud to add our ablator to CONMED’s
highly-recognized family of brands that have been at the forefront
of technological innovation for a growing range of minimally
invasive and orthopedic surgery procedures.”
Commenting on the agreement, Nate Folkert, VP and General
Manager of CONMED Orthopedic Division said, “We are excited to
execute this agreement, which allows our global salesforce to offer
this complementary product to our existing array of ablation
offerings. The UltrAblator is an innovative and economical option
that is highly compatible with customers’ existing electrosurgical
equipment. This agreement is in line with our commitment to
providing a full range of ablator products that cover a variety of
arthroscopic procedures for small and large joints, and are
competitively priced to enable the surgeon and facility to share in
cost savings.”
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented new
plasma-based surgical product for cutting and coagulation.
J-Plasma® utilizes a helium ionization process to produce a stable,
focused beam of ionized gas that provides surgeons with greater
precision, minimal invasiveness and an absence of conductive
currents through the patient during surgery. Bovie Medical
Corporation is also a leader in the manufacture of a range of
electrosurgical products and technologies, marketed through both
private labels and the Company’s own well-respected brands (Bovie®,
Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company’s current and new products,
please refer to the Investor Relations section of Bovie Medical
Corporation’s www.boviemed.com.
About CONMED Corporation
CONMED is a medical technology company that provides
surgical devices and equipment for minimally invasive procedures.
The Company’s products are used by surgeons and physicians in a
variety of specialties, including orthopedics, general surgery,
gynecology, neurosurgery, and gastroenterology. The Company
distributes its products worldwide from several manufacturing
locations. CONMED has a direct selling presence in 17
countries, and international sales constitute approximately 50% of
the Company’s total sales. Headquartered in Utica, New York,
the Company employs approximately 3,400 people. For more
information, visit www.conmed.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170119005256/en/
Investor Relations:Bovie Medical CorporationMBS Value
PartnersLynn Morgen/Jane
Searle212-750-5800investor.relations@boviemed.comorCONMED
CorporationLuke A. PomilioChief Financial
Officer315-624-3202LukePomilio@conmed.com
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Apr 2024 to May 2024
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From May 2023 to May 2024